Albany, NY, April 15, 2015 (GLOBE NEWSWIRE) -- Meningococcal disease is caused by the bacterium Neisseria meningitidis and occurs sporadically throughout the world with seasonal variations. It accounts for a proportion of endemic bacterial meningitis, which can progress very rapidly leading to death within 24 hours from the onset of symptoms. The disease is often misinterpreted as common flu in most of the cases. Five out of the several serogroups are known to cause meningococcal disease. The serogroups responsible for causing the disease comprise A, B, C, Y and W-135. The causative agent N. meningitidis is commonly found in the nasopharynx of humans and gets transmitted through droplet inhalation by means of close contact such as exposure to smokers, crowded living conditions such as dormitories, certain inherited disorders of the immune system, functional/anatomical asplenia or through intimate oral contact among others. According to the European Federation of Pharmaceutical Industries and Association, every year, meningitis affects almost 500,000 people globally, primarily affecting toddlers, infants and young adults, due to weaker immune system.
Browse Full Market Research of Meningococcal Vaccines Market: http://www.transparencymarketresearch.com/meningococcal-vaccines-market.html
The global market for meningococcal vaccines is segmented broadly into vaccine types namely, polysaccharide, conjugate, combination and Men B vaccines. The report also provides analysis for vaccine under development, NmVac4-DT by JN- International that is expected to be commercialized during the forecast period 2014 to 2022. The vaccine types are further segmented by different brands available in the market. The conjugate vaccines segment is likely to lead the overall meningococcal vaccines market in terms of revenue, which is estimated to be worth USD 2,655.0 million by 2022 at a CAGR of 8.9%. According to Department of Health, U.K., Bexsero is the first serogroup B vaccine to be incorporated into the national immunization program and is expected to be available in the market for sales post settle of price negotiations. The U.S. FDA recently approved two Men B vaccines: Trumenba by Pfizer in October 2014 and Bexsero by Novartis in January 2015.
Browse Press Release of Meningococcal Vaccines Market: http://www.transparencymarketresearch.com/pressrelease/meningococcal-vaccines-market.htm
The market for meningococcal vaccines is largely driven by increasing government intervention in reforming the healthcare infrastructure and incorporation of legislations specific to meningococcal vaccination. The public-private partnerships for conducting research and development, and manufacturing of quality vaccines at an affordable price are also contributing positively in driving market growth. Awareness campaigning from government and non-profit organizations, and obligatory immunization for individuals heading to Mecca (for Hajj pilgrimage) and the South African meningitis belt will also contribute to growth of this market. High cost of few but vital vaccines, such as Bexsero, and need for efficient cold chain logistics to maintain safety and efficacy of the vaccine are expected to be some of the major factors posing a challenge to the adequate uptake of these vaccines.
Get Full Report and TOC of Meningococcal Vaccines Market: http://www.transparencymarketresearch.com/sample/sample.php?flag=s&rep_id=1666
The key players dominating the global meningococcal vaccines market include Sanofi Pasteur (the vaccine division of Sanofi SA), Novartis International AG and GSK plc. These players account for more than 90% of the meningococcal vaccines market. Players such as Serum Institute of India Ltd., JN International Medical Corporation, Biomed Pvt. Ltd., Nuron Biotech and Baxter account for the remaining market share.
Other Reports By Transparency Market Research :
- Auto-Injectors Market: http://www.transparencymarketresearch.com/global-auto-injectors-market.html
- Capnography Equipment Market: http://www.transparencymarketresearch.com/capnography-market.html
The global meningococcal vaccines market is segmented as follow:
Meningococcal Vaccines Market, by Type
Polysaccharide Vaccines, by Brand
- Menomune
- Mencevax
- NmVac4
- Others
- Quadri Meningo
- Bi Meningo
Conjugate Vaccines, by Brand
- Menactra
- Menveo
- NeisVac-C
- Nimenrix
- Meningitec
- Menjugate
- MenAfriVac
Combination Vaccines, by Brand
- MenHibrix
- Menitorix
- NmVac4-DT
Men B Vaccines, by Brand
- Bexsero
- Trumenba
Meningococcal Vaccines Market, by Geography
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- Rest of Europe
Asia Pacific
- Japan
- Australia
- Rest of Asia Pacific
Rest of the World
- Latin America
- Africa
- Rest of RoW
Browse All Medical Market Research Reports: http://www.transparencymarketresearch.com/medical-devices-market-reports-6.html
About Us :
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.